Patents by Inventor David A. Low

David A. Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10265380
    Abstract: Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: April 23, 2019
    Assignees: Amarantus Bioscience Holdings, Inc., University of Massachusetts
    Inventors: Lawrence M. Schwartz, Gerald Commissiong, David A. Lowe, Roman Urfer
  • Publication number: 20180263975
    Abstract: This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering eltoprazine or a pharmaceutically acceptable acid addition salt thereof in doses and dosing schedules which result in beneficial antidyskinetic effects for the subject. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses and dosing regimens of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.
    Type: Application
    Filed: January 13, 2016
    Publication date: September 20, 2018
    Inventors: David A. Lowe, Charlotte Keywood
  • Publication number: 20170072015
    Abstract: Disclosed herein are methods of treating or preventing cell death-related sensory cell loss in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject. Also disclosed are methods of treating or preventing drug-induced ototoxicity in a subject in need thereof, the method comprising administering an effective amount of one or more neuroprotective peptides to the subject.
    Type: Application
    Filed: March 3, 2015
    Publication date: March 16, 2017
    Inventors: Lawrence M. Schwartz, Gerald Commissiong, David A. Lowe, Roman Urfer
  • Publication number: 20110156400
    Abstract: A kinetic energy rotation system is disclosed which comprises a plurality of wind powered generators. A motor rotates the wind powered generators in a horizontal plane and stores kinetic energy due to the rotating mass of the wind powered generators and its support platform. As electricity is generated by the wind powered generators, a portion of the generated electricity is fed back into the motor to maintain the rotation of the wind powered generators. Excess electricity may be redirected to the city's electrical grid, or other local electrical needs.
    Type: Application
    Filed: December 31, 2009
    Publication date: June 30, 2011
    Inventor: David A. Lowe
  • Patent number: 7705017
    Abstract: The present invention relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The present invention also relates to methods of preparation of hydroxamic acid HDAC inhibitor compounds of the invention, which are N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, and their incorporation into pharmaceutical compositions and methods of administration. The present invention also relates to N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, which may be prepared as a hydroxamic acid HDAC inhibitor compound library that can be utilized in screening methods known in the art.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: April 27, 2010
    Assignee: En Vivo Pharmaceuticals, Inc.
    Inventors: Christopher J. Cummings, David A. Lowe, William C. Ripka
  • Publication number: 20080317762
    Abstract: Contemplated compositions and methods relate to bacterial contact inhibition that is conferred by two gene products, CdiA and CdiB, which are encoded by the genes cdiA and cdiB, respectively. A further gene product CdiI, encoded by the gene cdiI confers immunity to contact inhibition caused by CdiAB.
    Type: Application
    Filed: August 16, 2006
    Publication date: December 25, 2008
    Inventors: Stephanie Aoki, Rupinderjit Pamma, Bruce Braaten, Aaron Hernday, Jessica Erin Bickham, David A. Low
  • Patent number: 7026155
    Abstract: Bacteria and in particular pathogenic bacteria are treated in a manner which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The alteration results in a change in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds which inhibit proliferation of bacteria are useful in treating bacterial infections.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: April 11, 2006
    Assignee: Regents of the University of California
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L Sinsheimer
  • Publication number: 20040255342
    Abstract: The present invention discloses a transgenic fly that expresses the Iowa mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Iowa peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
    Type: Application
    Filed: May 25, 2004
    Publication date: December 16, 2004
    Applicant: EnVivo Pharmaceuticals, Inc.
    Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
  • Publication number: 20040255341
    Abstract: The present invention discloses a transgenic fly that expresses the Arctic mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Arctic peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
    Type: Application
    Filed: May 25, 2004
    Publication date: December 16, 2004
    Applicant: EnVivo Pharmaceuticals, Inc.
    Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
  • Publication number: 20040250302
    Abstract: The present invention discloses a transgenic fly that expresses the Dutch mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Dutch peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
    Type: Application
    Filed: May 25, 2004
    Publication date: December 9, 2004
    Applicant: EnVivo Pharmaceuticals, Inc.
    Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
  • Publication number: 20040244064
    Abstract: The present invention discloses a transgenic fly that expresses the Flemish mutant version of the human A&bgr;42 peptide of human amyloid-&bgr; precursor protein (APP), and a double transgenic fly that expresses both the Tau protein and the human A&bgr;42Flemish peptide of human amyloid-&bgr; precursor protein (APP). The transgenic flies of the present invention provide for models of neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying genetic modifiers, as well as screening methods to identify therapeutic compounds to treat neurodegenerative disorders using the transgenic flies.
    Type: Application
    Filed: May 25, 2004
    Publication date: December 2, 2004
    Applicant: EnVivo Pharmaceuticals, Inc.
    Inventors: David A. Lowe, Gerhard Koenig, Christopher J. Cummings
  • Patent number: 6800465
    Abstract: The present invention relates to a novel D-hydantoinase from Ochrobactrum anthropi that enantio-selectively hydrolyzes D-hydantoins to their corresponding D-N-carbamoyl-amino acids; nucleic acids that encode for the enzyme; expression vectors including the nucleic acids; and host cells capable of expressing the enzyme.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: October 5, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Politino, Sean M. Tonzi, Guna Romancik, John J. Usher, David A. Lowe
  • Publication number: 20030013102
    Abstract: The present invention relates to a novel D-hydantoinase from Ochrobactrum anthropi that enantio-selectively hydrolyzes D-hydantoins to their corresponding D-N-carbamoyl-amino acids; nucleic acids that encode for the enzyme; expression vectors including the nucleic acids; and host cells capable of expressing the enzyme.
    Type: Application
    Filed: April 3, 2002
    Publication date: January 16, 2003
    Inventors: Michael Politino, Sean M. Tonzi, Guna Romancik, John J. Usher, David A. Lowe
  • Publication number: 20020086332
    Abstract: Bacteria and in particular pathogenic bacteria are treated in a manner which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The alteration results in a change in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds which inhibit proliferation of bacteria are useful in treating bacterial infections.
    Type: Application
    Filed: August 9, 2001
    Publication date: July 4, 2002
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L. Sinsheimer
  • Publication number: 20020086032
    Abstract: The present invention is directed towards methods of producing antibodies using an attenuated strain of pathogenic bacteria (e.g. Haemophilus, E. coli, and/or Salmonella) having non-reverting genetic mutations relative to the wild-type organism which alter activity of DNA adenine methylase (Dam). The invention further includes compositions comprised of the attenuated bacteria and methods using these compositions to elicit an immune response and immunize a subject with highly specific antibodies. The invention also provides methods producing antibodies to heterologous antigens which the attenuated bacteria are engineered to produce.
    Type: Application
    Filed: August 9, 2001
    Publication date: July 4, 2002
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L. Sinsheimer
  • Publication number: 20020081317
    Abstract: Immunogenic compositions are disclosed which are comprised of bacteria which are pathogenic in their native state but which are rendered non-pathogenic in a manner which alters the native level or activity of DNA adenine methylase. The genome is also artificially engineered to express a heterologous antigen such as an immunogenic antigen of a virus, protozoa, parasite or fungi.
    Type: Application
    Filed: August 9, 2001
    Publication date: June 27, 2002
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L. Sinsheimer
  • Publication number: 20020077272
    Abstract: The virulence of bacterial strains and in particular pathogenic bacteria which infect human is reduced by an agent which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The agent causes an alteration in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds and formulations thereof which reduce bacterial virulence inhibit proliferation of bacteria and are useful in treating bacterial infections, particularly in humans.
    Type: Application
    Filed: August 9, 2001
    Publication date: June 20, 2002
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L. Sinsheimer
  • Publication number: 20020076417
    Abstract: The present invention is directed towards an attenuated strain of pathogenic bacteria (e.g. Haemophilus, E. Coli, and/or Salmonella) having non-reverting genetic mutations relative to the wild-type organism which alter activity of DNA adenine methylase (Dam). The invention further includes compositions comprised of the attenuated bacteria and methods using these compositions to elicit an immune response to produce highly specific antibodies. The invention also provides methods for preparing vaccines as well as screening methods to identify agents which may have anti-bacterial activity.
    Type: Application
    Filed: August 9, 2001
    Publication date: June 20, 2002
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L. Sinsheimer
  • Publication number: 20020068068
    Abstract: The present invention is directed towards compositions containing pathogenic bacteria (e.g. Haemophilus, E. Coli, and/or Salmonella) having non-reverting genetic mutations which alter activity of DNA adenine methylase (Dam) and methods using these compositions to elicit an immune response to produce highly specific antibodies. The invention also provides methods for preparing vaccines as well as screening methods to identify agents which may have anti-bacterial activity.
    Type: Application
    Filed: August 9, 2001
    Publication date: June 6, 2002
    Inventors: Michael J. Mahan, Douglas M. Heithoff, David A. Low, Robert L. Sinsheimer
  • Patent number: 6070172
    Abstract: A file system configuration is scored by summing the squares of the sizes of each contiguous section of free space. A set of defragmentation plans, each describing a sequence of file movements, is generated and scored. The defragmentation plan with the highest score is chosen and executed. In moving a file, a temporary file of the same size is created and the file is copied to the temporary file. After the copying, the temporary file is designated as the file, and the file system space originally occupied by the file is unallocated.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: May 30, 2000
    Assignee: Oracle Corporation
    Inventor: David A. Lowe